Moving Toward Biomarker-Driven Care in Bladder Cancer
Benjamin Garmezy, MD
A Long-Term View of Cardiovascular Risk After Cancer Treatment
Stephanie Dixon, MD, MPH
Moving Beyond Chemotherapy in Mantle Cell Lymphoma Care
Jonathon Cohen, MD, MS
Supportive Care Before CLL Treatment: Infection Risk and Comorbidity Management
Kerry A. Rogers, MD
Supportive Care During and After CLL Treatment: What to Prioritize
How Myeloid Mutations in ALL Inform Treatment Decisions
Caner Saygin, MD
Adapting CV Risk Reduction Strategies for Cancer Survivorship
A Look at WCLC 2026: Pivotal Trials and Emerging Directions
Triparna Sen, PhD
Making the Most of WCLC 2026: A Guide for Early-Career Professionals
Closing Gaps in CRC Screening: From Stool-Based Testing to Timely Colonoscopy
Shelina Ramnarine, PhD
David A. Johnson, MD, FACG, FACP
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
Komal Jhaveri, MD, FACP
Virginia Kaklamani, MD, DSc
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
Oral SERDs and PROTACs in ER+/HER2− mBC: Testing Smarter, Treating Better
Closing the Evidence Gap in Metastasis-Directed Therapy for mBC
Lajos Pusztai, MD, DPhil
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients With Multiple Myeloma
Saad Z. Usmani, MD, MBA
The Frontline Imperative: Integrating Anti-CD38–Based Regimens Into Multiple Myeloma Care in Community Practice
Natalie S. Callander, MD
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.